Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.01 USD

16.01
12,370,961

+0.30 (1.91%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.05 +0.04 (0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sejuti Banerjea headshot

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

by Sejuti Banerjea

The WHO's Solidarity testing project could be good news for the world.

Zacks Equity Research

Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma

by Zacks Equity Research

Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.90, moving +0.77% from the previous trading session.

Zacks Equity Research

Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.

Zacks Equity Research

Novartis to Donate Generic Hydroxychloroquine for Coronavirus

by Zacks Equity Research

Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.26, marking a +1.26% move from the previous day.

Ekta Bagri headshot

Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus

by Ekta Bagri

Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

Zacks Equity Research

J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.

by Zacks Equity Research

Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.

Zacks Equity Research

Mallinckrodt Up on New York's Support for Opioid Settlement

by Zacks Equity Research

Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.

Zacks Equity Research

J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe

by Zacks Equity Research

Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio

Zacks Equity Research

Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4

by Zacks Equity Research

Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.

Zacks Equity Research

Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat

by Zacks Equity Research

Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.

Zacks Equity Research

Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings

by Zacks Equity Research

Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

Zacks Equity Research

Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

Manaswita Ghosh Dutta headshot

3 Best Drugmakers That Are Immune to Coronavirus Fright

by Manaswita Ghosh Dutta

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

Zacks Equity Research

Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize

by Zacks Equity Research

Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.

Zacks Equity Research

Teva (TEVA) Q4 Earnings In Line, Sales Beat, Stock Up

by Zacks Equity Research

Teva Pharmaceutical (TEVA) matches earnings estimates but beats the same for sales. Shares rise in pre-market trading.

Zacks Equity Research

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session.

Zacks Equity Research

Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal

by Zacks Equity Research

Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.

Zacks Equity Research

Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

by Zacks Equity Research

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

Zacks Equity Research

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Zacks Equity Research

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Zacks Equity Research

J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

by Zacks Equity Research

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.